ALK Inhibitors, a Pharmaceutical Perspective

@inproceedings{Ardini2012ALKIA,
  title={ALK Inhibitors, a Pharmaceutical Perspective},
  author={Elena Ardini and Arturo Galvani},
  booktitle={Front. Oncol.},
  year={2012}
}
In 2007, the ALK tyrosine kinase was described as a potential therapeutic target for a subset of non-small-cell lung cancer patients. Clinical proof of concept, culminating in the recent approval by the Food and Drug Administration of the Pfizer drug crizotinib followed in record time. The drug was approved together with a companion diagnostic for detection of patients eligible for therapy. This remarkable example of the coming of age of personalized medicine in cancer therapy is hopefully only… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

ALK inhibitors in lung cancer

  • D. Camidge
  • European Society for Medical Oncology (ESMO…
  • 2011
1 Excerpt

Acti - vatingALKmutations found in neuroblastoma are inhibited by crizotinib and NVPTAE 684

  • N. P. Shah, J. M. Nicoll, +4 authors C. L. Sawyers
  • Biochem . J .
  • 2011

Activity of a potent and selective phase I ALK inhibitor LDK378 in naïve and crizotinib-resistant preclinical

  • T. H. Marsilje, P. McNamara, J. Harris
  • 2011

Effect of crizotinib

  • R. C. bele, Y. J. Bang, +7 authors D. R. Camidge
  • 2011

Similar Papers

Loading similar papers…